namuscla
lupin europe gmbh - mexiletine hydrochloride - Миотонических poremećaja - srčana terapija - namuscla indiciran za simptomatsko liječenje миотонии u odraslih bolesnika s non-дистрофические миотонических poremećaja.
hydrocortisone aceponate ecuphar (previously cortacare)
ecuphar - hidrokortizon aceponat - kortikosteroidi, dermatološki pripravci - psi - za simptomatsko liječenje upalnih i prurijskih dermatoza kod pasa. for alleviation of clinical signs associated with atopic dermatitis in dogs.
isturisa
recordati rare diseases - osilodrostat fosfat - cushingov sindrom - kortikosteroidi za sistemsku upotrebu - isturisa propisan za liječenje endogene cushingov sindrom u odraslih.
sogroya
novo nordisk a/s - somapacitan - rast - hipofiza i hipotalamusni hormoni i analozi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).
vazkepa
amarin pharmaceuticals ireland limited - icosapent ethyl - dislipidemije - sredstva za modifikaciju lipida - indicated to reduce cardiovascular risk as an adjunct to statin therapy.
ryeqo
gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - uterusa - hipofiza i hipotalamusni hormoni i analozi - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
tolvaptan accord
accord healthcare s.l.u. - Толваптан - neprimjereni adh sindrom - diuretici, - tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (siadh).
abasaglar (previously abasria)
eli lilly nederland b.v. - inzulin glargin - Šećerna bolest - lijekovi koji se koriste u dijabetesu - liječenje dijabetes melitusa kod odraslih, adolescenata i djece u dobi od 2 godine i više.